Pegylated liposomal doxorubicin (PLD) treatment for recurrent epithelial ovarian cancer (rEOC): Implications of BRCA mutations.

2010 ◽  
Vol 28 (15_suppl) ◽  
pp. 5043-5043 ◽  
Author(s):  
T. Safra ◽  
L. Borgato ◽  
M. Nicoletto ◽  
L. Rolnitzky ◽  
J. Curtin ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Epithelial Ovarian Cancer ◽  
Liposomal Doxorubicin ◽  
Pegylated Liposomal Doxorubicin ◽  
Brca Mutations

Efficacy and toxicity of prolonged pegylated liposomal doxorubicin use in women with recurrent epithelial ovarian cancer

2020 ◽  
Vol 158 (2) ◽  
pp. 309-315 ◽  
Author(s):  
Laura M. Chambers ◽  
Adam Pendlebury ◽  
Peter G. Rose ◽  
Meng Yao ◽  
Robert DeBernardo
Keyword(s):  
Ovarian Cancer ◽  
Epithelial Ovarian Cancer ◽  
Liposomal Doxorubicin ◽  
Pegylated Liposomal Doxorubicin

scholarly journals A high response rate to liposomal doxorubicin is seen among women with BRCA mutations treated for recurrent epithelial ovarian cancer

2011 ◽  
Vol 123 (3) ◽  
pp. 486-491 ◽  
Author(s):  
Sarah F. Adams ◽  
Evelyn B. Marsh ◽  
Wafic Elmasri ◽  
Steffanie Halberstadt ◽  
Stephanie VanDecker ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Epithelial Ovarian Cancer ◽  
Liposomal Doxorubicin ◽  
Response Rate ◽  
High Response Rate ◽  
High Response ◽  
Brca Mutations
Sign in / Sign up

Export Citation Format

Share Document